Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
99% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. CYTR: No Debt )
CYTR' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: No Debt

Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
80% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 0.41
M-Score: 11.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -9198.00
CYTR's Operating margin (%) is ranked higher than
50% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. CYTR: -9198.00 )
CYTR' s 10-Year Operating margin (%) Range
Min: -21052   Max: -21.16
Current: -9198

-21052
-21.16
Net-margin (%) -15828.33
CYTR's Net-margin (%) is ranked lower than
51% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CYTR: -15828.33 )
CYTR' s 10-Year Net-margin (%) Range
Min: -18984.04   Max: 408
Current: -15828.33

-18984.04
408
ROE (%) -445.41
CYTR's ROE (%) is ranked lower than
51% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CYTR: -445.41 )
CYTR' s 10-Year ROE (%) Range
Min: -1454.89   Max: 1.33
Current: -445.41

-1454.89
1.33
ROA (%) -114.42
CYTR's ROA (%) is ranked higher than
52% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. CYTR: -114.42 )
CYTR' s 10-Year ROA (%) Range
Min: -324.66   Max: 1.11
Current: -114.42

-324.66
1.11
ROC (Joel Greenblatt) (%) -15768.00
CYTR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. CYTR: -15768.00 )
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -444700   Max: -24.14
Current: -15768

-444700
-24.14
EBITDA Growth (%) -7.20
CYTR's EBITDA Growth (%) is ranked higher than
77% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CYTR: -7.20 )
CYTR' s 10-Year EBITDA Growth (%) Range
Min: -67.3   Max: 144.7
Current: -7.2

-67.3
144.7
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

CYTR Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

Paul Tudor Jones 51,898 sh (New)
George Soros 81,800 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $2.92 - $5.31 $ 3.18-16%0
George Soros 2014-03-31 New Buy$3.18 - $8.08 $ 3.18-47%81800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
CYTR's P/B is ranked higher than
86% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CYTR: 2.20 )
CYTR' s 10-Year P/B Range
Min: 1.14   Max: 64.65
Current: 2.2

1.14
64.65
P/S 1402.10
CYTR's P/S is ranked lower than
75% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. CYTR: 1402.10 )
CYTR' s 10-Year P/S Range
Min: 0   Max: 1460.1
Current: 1402.1

0
1460.1
Current Ratio 4.67
CYTR's Current Ratio is ranked higher than
74% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. CYTR: 4.67 )
CYTR' s 10-Year Current Ratio Range
Min: 1.04   Max: 75.75
Current: 4.67

1.04
75.75
Quick Ratio 4.67
CYTR's Quick Ratio is ranked higher than
76% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYTR: 4.67 )
CYTR' s 10-Year Quick Ratio Range
Min: 1.04   Max: 75.75
Current: 4.67

1.04
75.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.20
CYTR's Price/Net Cash is ranked higher than
96% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTR: 2.20 )
CYTR' s 10-Year Price/Net Cash Range
Min: 0.57   Max: 458
Current: 2.2

0.57
458
Price/Net Current Asset Value 2.20
CYTR's Price/Net Current Asset Value is ranked higher than
96% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. CYTR: 2.20 )
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.44   Max: 601.65
Current: 2.2

0.44
601.65
Price/Tangible Book 2.10
CYTR's Price/Tangible Book is ranked higher than
89% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. CYTR: 2.10 )
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.32   Max: 65.43
Current: 2.1

0.32
65.43
Price/Median PS Value 3.10
CYTR's Price/Median PS Value is ranked higher than
51% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYTR: 3.10 )
CYTR' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 11.22
Current: 3.1

0.01
11.22
Earnings Yield (Greenblatt) 39.10
CYTR's Earnings Yield (Greenblatt) is ranked higher than
83% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CYTR: 39.10 )
CYTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 57.8
Current: 39.1

5.2
57.8
Forward Rate of Return (Yacktman) -18.43
CYTR's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CYTR: -18.43 )
CYTR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -165.8   Max: -85.3
Current: -18.43

-165.8
-85.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany
CytRx Corporation is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, it has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, completed a Phase 1b/2 clinical trial mainly in the same indication and initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally designed, inhibitor of several Src kinases developed by the Japanese pharmaceutical company Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia, or CML. In addition to its Bcr-Abl inhibitory properties, bafetinib is a potent and specific inhibitor of Lyn and Fyn kinases. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin and tamibarotene in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide